PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse

    PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der
Schweizer Börse

^
EQS Group-News: PolyPeptide Group / Schlagwort(e): Börsengang
PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und
beginnt Handel an der Schweizer Börse

29.04.2021 / 07:00

---------------------------------------------------------------------------

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY
OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA
OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL.

FOR RELEASE IN SWITZERLAND - THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS
COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.


PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und
beginnt Handel an der Schweizer Börse

Zug, 29. April 2021 - PolyPeptide Group AG («PolyPeptide» oder «die
Gruppe»), ein weltweit führender Entwickler und Hersteller von Peptiden, hat
das Bookbuilding-Verfahren ihres Börsengangs (IPO) erfolgreich abgeschlossen
und den Angebotspreis bei CHF 64.00 pro Aktie festgelegt. Die Kotierung der
Aktien und der Beginn des Handels an der Schweizer Börse (SIX) unter dem
Tickersymbol «PPGN» erfolgen heute.

- Der IPO-Angebotspreis von PolyPeptide wurde bei CHF 64.00 pro Aktie
festgelegt, was eine Marktkapitalisierung von CHF 2'120 Millionen
impliziert.

- Das Angebot war mit einer starken Nachfrage von Schweizer und
internationalen Investoren mehrfach überzeichnet.

- Der Streubesitz (Free Float) beträgt rund 35% vor einer allfälligen
Ausübung der Mehrzuteilungsoption und 40% im Falle einer vollständigen
Ausübung der Mehrzuteilungsoption.

- Die Aktien von PolyPeptide (SIX: PPGN) werden heute kotiert und ab heute
an der SIX gehandelt.

Peter Wilden, Präsident des Verwaltungsrates von PolyPeptide: «Mit einer
fokussierten Strategie seit den Anfängen im Jahr 1952 hat sich PolyPeptide
zu einem führenden Anbieter entwickelt. Heute stellt das Unternehmen rund
die Hälfte aller derzeit zugelassenen Peptidwirkstoffe her. Die Kotierung an
der SIX ist ein wichtiger Meilenstein in der Geschichte unseres
Unternehmens, soll aber auch als starkes Zeichen unserer Ambition gesehen
werden, Innovation zum Nutzen von Patienten auf der ganzen Welt
voranzutreiben. Mein Dank gilt dem PolyPeptide-Team und allen, die dazu
beigetragen haben, dies zu erreichen.»

Im Rahmen des Börsengangs haben die Syndikatsbanken erfolgreich 3'125'000
neue Aktien sowie 8'396'740 bestehende Aktien, die vom Alleinaktionär der
Gruppe, Draupnir Holding B.V., angeboten wurden, jeweils zu einem
Angebotspreis von CHF 64.00 pro Aktie platziert. Zudem hat der verkaufende
Aktionär eine Mehrzuteilungsoption von bis zu 1'728'261 bestehenden Aktien
gewährt, die zum Angebotspreis innerhalb von 30 Kalendertagen nach dem
ersten Handelstag ganz oder teilweise ausgeübt werden kann, was ein
Platzierungsvolumen von insgesamt bis zu CHF 848 Millionen impliziert.

Basierend auf dem Angebotspreis beläuft sich die implizite
Marktkapitalisierung von PolyPeptide auf CHF 2'120 Millionen. Der
Streubesitz beträgt vor einer allfälligen Ausübung der Mehrzuteilungsoption
rund 35%. Unter der Annahme einer vollständigen Ausübung der
Mehrzuteilungsoption wird der Streubesitz 40% betragen, und Draupnir Holding
B.V. wird einen Anteil von 60% am Unternehmen behalten.

Wie beabsichtigt, erzielte PolyPeptide durch den Verkauf der neuen Aktien im
Rahmen des Angebots einen Bruttoerlös von CHF 200 Millionen; dieser soll
dazu verwendet werden, die laufenden Investitionsausgaben zu beschleunigen,
die Expansion der Gruppe in verwandte Geschäftsbereiche voranzutreiben und
längerfristig allenfalls weitere organische und nicht-organische
Wachstumsmöglichkeiten zu verfolgen.

Raymond De Vré, Chief Executive Officer von PolyPeptide: «Der erfolgreiche
Börsengang ist eine Anerkennung der ausserordentlichen Erfolgsbilanz von
PolyPeptide und dessen Team, das sich stets dafür einsetzt, auch die
höchsten Kundenerwartungen zu erfüllen. Für die Zukunft wollen wir nun auch
den Erwartungen unserer Investoren gerecht werden und ihr Vertrauen
verdienen, und wir freuen uns auf die weiteren Kontakte mit den
Marktteilnehmern.»

Credit Suisse, Morgan Stanley und BofA Securities fungieren als Joint Global
Coordinators und Joint Bookrunners für den Börsengang. Berenberg, Danske
Bank und Zürcher Kantonalbank fungieren als Joint Bookrunners. Rothschild &
Co. ist unabhängiger Finanzberater von PolyPeptide Group und Draupnir
Holding B.V.

Wichtige IPO-Informationen und indikativer IPO-Zeitplan

   Eckdaten
   Börsenkotierung                             Schweizer Börse SIX
                                               (International Reporting
                                               Standard)
   Ticker                                      PPGN
   Valorennummer                               111 076 085
   ISIN                                        CH1110760852
   Nennwert                                    CHF 0.01 pro Namenaktie
   Angebotspreis                               CHF 64.00 pro Aktie
   Basisangebot                                3'125'000 neue Aktien
                                               8'396'740 bestehende Aktien
   Mehrzuteilungsoption («Greenshoe»)          Bis zu 1'728'261 bestehende
                                               Aktien (15% des
                                               Basisangebots)
   Anzahl ausstehende Aktien                   33'125'001 Aktien
   Indikativer IPO-Zeitplan
   Kotierung und erster Handelstag             29. April 2021
   Einbuchung/Lieferung der angebotenen        3. Mai 2021
   Aktien gegen Bezahlung des
   Angebotspreises
   Letzter Tag zur Ausübung der                28. Mai 2021
   Mehrzuteilungsoption
Kontakt

PolyPeptide Group
Michael Stäheli, Head of Investor Relations & Corporate Communications
[e-mail]
[phone]

Lemongrass Communications
[e-mail], [e-mail]
[phone]


Über PolyPeptide Group

PolyPeptide ist ein Auftragsentwickler und -Hersteller (CDMO) im Bereich
proprietärer und generischer Peptide in GMP-Qualität, die von Pharma- und
Biotech-Unternehmen in zugelassenen pharmazeutischen Produkten, Medikamenten
in der klinischen Entwicklung sowie in Generika eingesetzt werden. Das
Unternehmen, dessen Anfänge ins Jahr 1952 zurückreichen, stellt heute rund
die Hälfte aller derzeit zugelassenen Peptidwirkstoffe her und verfügt über
eine globale Präsenz mit sechs GMP-zertifizierten Produktionsanlagen in
Europa, den USA und Indien. Als multinationales Unternehmen mit über 900
Mitarbeitenden vereint PolyPeptide umfassendes Wissen und Erfahrung.
PolyPeptide ist organisch und durch selektive Akquisitionen bestehender
Expertise gewachsen und ist heute ein führendes Unternehmen in der
ausgelagerten Peptidherstellung. Die Aktien von PolyPeptide (SIX: PPGN) sind
an der Schweizer Börse kotiert. Weitere Informationen finden Sie unter
polypeptide.com.

PolyPeptide Group AG, Dammstrasse 19, 6300 Zug, Schweiz

Disclaimer

This document is not an offer to sell or a solicitation of offers to
purchase or subscribe for shares. This document is not a prospectus within
the meaning of the Swiss Financial Services Act and not a prospectus under
any other applicable laws. Copies of this document may not be sent to
jurisdictions, or distributed in or sent from jurisdictions, in which this
is barred or prohibited by law. The information contained herein shall not
constitute an offer to sell or the solicitation of an offer to buy, in any
jurisdiction in which such offer or solicitation would be unlawful prior to
registration, exemption from registration or qualification under the
securities laws of any jurisdiction.

A decision to invest in securities of PolyPeptide Group should be based
exclusively on the offering prospectus published by PolyPeptide Group AG
(the "Company") for such purpose. Copies of the offering prospectus and any
other supplements to the offering prospectus are/will be available free of
charge in Switzerland for 12 months following the first day of trading on
SIX Swiss Exchange at Credit Suisse AG, Zurich, Switzerland (email:
[e-mail]). In addition, copies of the offering
prospectus and any other supplements to the offering prospectus are/will be
available free of charge in Switzerland from PolyPeptide Group AG, Investor
Relations, Dammstrasse 19, 6300 Zug, Switzerland (phone: [phone];
email: [e-mail]).

This document is not for publication or distribution in the United States of
America (including its territories and possessions, any State of the United
States and the District of Columbia), Canada, Japan or Australia or any
other jurisdiction into which the same would be unlawful. This document does
not constitute an offer or invitation to subscribe for or purchase any
securities in such countries or in any other jurisdiction into which the
same would be unlawful. In particular, the document and the information
contained herein should not be distributed or otherwise transmitted into the
United States of America or to publications with a general circulation in
the United States of America. The securities referred to herein (the
"Securities")
have not been and will not be registered under the U.S. Securities Act of
1933, as amended (the "Securities Act"), or the laws of any state, and may
not be offered or sold in the United States of America absent registration
under or an exemption from registration under the Securities Act. There will
be no public offering of the Securities in the United States of America.

This document does not constitute an "offer of securities to the public"
within the meaning of Regulation (EU) 2017/1129 as it forms part of domestic
law by virtue of the European Union (Withdrawal) Act 2018 (the "UK
Prospectus Regulation") of the Securities in the United Kingdom (the "UK").
Any offers of the Securities in the UK will be made pursuant to an exemption
under the UK Prospectus Regulation from the requirement to produce a
prospectus for offers of the Securities. In the UK, this document is only
addressed to qualified investors within the meaning of the UK Prospectus
Regulation. In addition, this document is only being distributed to and is
only directed at (i) persons who are outside the United Kingdom or (ii) to
investment professionals falling within article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FSMA
Order") or (iii) persons falling within Articles 49(2)(a) to (d), "high net
worth companies, unincorporated associations, etc." of the FSMA Order, and
(iv) persons to whom an invitation or inducement to engage in investment
activity within the meaning of Section 21 of the Financial Services and
Markets Act 2000 may otherwise be lawfully communicated or caused to be
communicated (all such persons together being referred to as "relevant
persons"). The Securities are only available to, and any invitation, offer
or agreement to subscribe, purchase or otherwise acquire such Securities
will be engaged in only with, relevant persons. Any person who is not a
relevant person should not act or rely on this document or any of its
contents.

This document does not constitute an "offer of securities to the public"
within the meaning of Regulation (EU) 2017/1129 of the European Union, as
amended (the "Prospectus Regulation") in any member state of the European
Economic Area (the "EEA"). Any offers of the Securities to persons in the
EEA will be made pursuant to an exemption under the Prospectus Regulation
from the requirement to produce a prospectus for offers of the Securities.
In any member state of the EEA, this document is only addressed to qualified
investors in that relevant member state within the meaning of the Prospectus
Regulation.

Identification of Target Market

Solely for the purposes of the product governance requirements contained
within: (a) EU Directive 2014/65/EU on markets in financial instruments, as
amended ("MiFID II"); (b) articles 9 and 10 of Commission Delegated
Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing
measures (together, the "MiFID II Product Governance Requirements"), and
disclaiming all and any liability, whether arising in tort, contract or
otherwise, which any "manufacturer" (for the purposes of the MiFID II
Product Governance Requirements) may otherwise have with respect thereto,
the Securities have been subject to a product approval process by each
underwriter (as defined below) established in the EEA, which has determined
that the Securities are: (i) compatible with an end target market of retail
investors and investors who meet the criteria of professional clients and
eligible counterparties, each as defined in MiFID II; and (ii) eligible for
distribution through all distribution channels as are permitted by MiFID II
(the "MiFID II Target Market Assessment").

Solely for the purposes of the product governance requirements of Chapter 3
of the FCA Handbook Product Intervention and Product Governance Sourcebook
(the "UK Product Governance Requirements"), and /or any equivalent
requirements elsewhere, and disclaiming all and any liability, whether
arising in tort, contract or otherwise, which any "manufacturer" (for the
purposes of the UK Product Governance Requirements and/or any equivalent
requirements elsewhere) may otherwise have with respect thereto, the
Securities have been subject to a product approval process by each
underwriter (as defined below) established in the UK, which has determined
that the Securities are: (i) compatible with an end target market of retail
investors and investors who meet the criteria of professional clients and
eligible counterparties, each as defined in Chapter 3 of the FCA Handbook
Conduct of Business Sourcebook; and (ii) eligible for distribution through
all permitted distribution channels (the "UK Target Market Assessment").

Notwithstanding the MiFID II Target Market Assessment and the UK Target
Market Assessment, distributors should note that: the price of the
Securities may decline and investors could lose all or part of their
investment; the Securities offer no guaranteed income and no capital
protection; and an investment in the Securities is compatible only with
investors who do not need a guaranteed income or capital protection, who
(either alone or in conjunction with an appropriate financial or other
adviser) are capable of evaluating the merits and risks of such an
investment and who have sufficient resources to be able to bear any losses
that may result therefrom.

The MiFID II Target Market Assessment and the UK Target Market Assessment
are without prejudice to any contractual, legal or regulatory selling
restrictions in relation to the offering of the Securities.

Furthermore, it is noted that, notwithstanding the MiFID II Target Market
Assessment, the underwriters (as defined below) established in the EEA will
only procure investors who meet the criteria of professional clients and
eligible counterparties under MiFID II and that, notwithstanding the UK
Target Market Assessment, the underwriters established in the UK will only
procure investors who meet the criteria of professional clients and eligible
counterparties under Chapter 3 of the FCA Handbook Conduct of Business
Sourcebook. For the avoidance of doubt, the MiFID II Target Market
Assessment and the UK Target Market Assessment do not constitute: (a) in the
case of the MiFID II Target Market Assessment, an assessment of suitability
or appropriateness for the purposes of MiFID II and in the case of the UK
Target Market Assessment, an assessment of suitability or appropriateness
for the purposes of Chapters 9A or 10A respectively of the FCA Handbook
Conduct of Business Sourcebook; or (b) a recommendation to any investor or
group of investors to invest in, or purchase, or take any other action
whatsoever with respect to the offered Securities. Each distributor is
responsible for undertaking its own relevant target market assessment in
respect of the offered Securities and determining appropriate distribution
channels.

This publication may contain specific forward-looking statements, e.g.
statements including terms like "believe", "assume", "expect", "forecast",
"project", "may", "could", "might", "will" or similar expressions. Such
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors which may result in a substantial divergence
between the actual results, financial situation, development or performance
of PolyPeptide Group and those explicitly or implicitly presumed in these
statements. Against the background of these uncertainties, readers should
not rely on forward-looking statements. PolyPeptide Group assumes no
responsibility to up-date forward-looking statements or to adapt them to
future events or developments.

Except as required by applicable law, PolyPeptide Group has no intention or
obligation to update, keep updated or revise this publication or any parts
thereof following the date hereof.

None of the underwriters (as defined below) or any of their respective
subsidiary undertakings, affiliates or any of their respective directors,
officers, employees, advisers, agents, alliance partners or any other entity
or person accepts any responsibility or liability whatsoever for, or makes
any representation, warranty or undertaking, express or implied, as to the
truth, accuracy, completeness or fairness of the information or opinions in
this announcement (or whether any information has been omitted from the
announcement) or any other information relating to the group, its
subsidiaries or associated companies, whether written, oral or in a visual
or electronic form, and howsoever transmitted or made available or for any
loss howsoever arising from any use of this announcement or its contents or
otherwise arising in connection therewith. Accordingly, each of the
underwriters and the other foregoing persons disclaim, to the fullest extent
permitted by applicable law, all and any liability, whether arising in tort
or contract or that they might otherwise be found to have in respect of this
announcement and/or any such statement.

Each of Credit Suisse AG, Morgan Stanley Europe SE, Merrill Lynch
International, Danske Bank A/S, Joh. Berenberg, Gossler & Co. KG and Zürcher
Kantonalbank (the "underwriters") is acting exclusively for PolyPeptide
Group and no one else in connection with any transaction referred to in this
document. Each of the underwriters will not regard any other person as a
client and will not be responsible to anyone other than PolyPeptide Group
for providing the protections afforded to their respective clients nor for
the giving of advice in relation to any transaction, matter or arrangement
referred to herein.

This publication includes industry and market information based on the
PolyPeptide Group's analysis of multiple internal and third party sources,
including information extracted from market research, governmental and other
publicly available information, independent industry publications and
information and reports prepared by consulting firms (which has been
produced based on publications comprising industry data, forecasts, market
and customer surveys, analyst reports, other consultant strategy reports and
other information made available to it by third party data providers,
industry associations, competitors, published accounts, interviews with key
market participants/primary interviews and virtual field visits it conducted
with industry experts and participants, secondary market research and
internal financial and operational information supplied by, or on behalf of,
the Group). Readers should be aware that market data and statistics are
inherently predictive and speculative and are not necessarily reflective of
actual or future market conditions. Such statistics are based on market
research, which itself is based on sampling and subjective judgments by both
the researchers and the respondents. In addition, the value of comparisons
of statistics of different markets is limited by many factors, including
that (i) the underlying information is gathered by different methods with
varying levels of access and information available in different markets and
(ii) different assumptions are applied in compiling the data. Market studies
are frequently based on information and assumptions that may not be exact or
appropriate and their methodology is by nature forward-looking and
speculative.


---------------------------------------------------------------------------

Ende der Medienmitteilungen

---------------------------------------------------------------------------

   Sprache:        Deutsch
   Unternehmen:    PolyPeptide Group
                   Dammstrasse 19
                   CH-6300 Zug
                   Schweiz
   Telefon:        [phone]
   E-Mail:         [e-mail]
   Internet:       www.polypeptide.com
   EQS News ID:    1190218



   Ende der Mitteilung    EQS Group News-Service
---------------------------------------------------------------------------

1190218 29.04.2021

°